4 news items
OpRegenĀ® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
LCTX
6 May 24
and logistics of having to use a dose preparation facility. The primary objective of the study was to evaluate the safety and tolerability of OpRegen as assessed
RG6501 (OpRegenĀ®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
LCTX
13 Mar 24
preparation facility. The primary objective of the study was to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency
Lineage Cell Therapeutics Announces OpRegen Preclinical Engraftment Results To Be Presented At 2024 Association For Research In Vision And Ophthalmology Meeting
LCTX
11 Mar 24
subretinal delivery," will be presented by Rachel N. Andrews, DVM, PhD, DACVP, Principal Scientist-Pathologist, Safety Assessment, Genentech, a member
RG6501 (OpRegenĀ®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
LCTX
11 Mar 24
," will be presented by Rachel N. Andrews, DVM, PhD, DACVP, Principal Scientist-Pathologist, Safety Assessment, Genentech, a member of the Roche Group, on behalf
- Prev
- 1
- Next